Leukemia

Until the last decade, efforts to develop a therapy that successfully targeted the KRAS mutation had been futile.

September is Blood Cancer Awareness Month.

COVID-19 variants pose a greater threat to certain patients with cancer, particularly those with hematologic malignancies, confirming the need to promote vaccination within this population, according to data presented at ESMO Congress 2021.

The FDA cleared an investigational new drug application for NTLA-5001, a T-cell receptor T-cell therapy designed to treat adults with relapsed or refractory acute myeloid leukemia.

The FDA granted fast track designation to VOR33, an engineered allogeneic stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse.

The FDA approved the first chimeric antigen receptor therapy in 2017, authorizing tisagenlecleucel for treatment of children or young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

Renier Brentjens, MD, PhD, has been appointed deputy director and chair of the department of medicine of Roswell Park Comprehensive Cancer Center.

Lachelle Dawn Weeks, MD, PhD, of Dana-Farber Cancer Institute and Emilio Ramos, MD, PhD, of University of California, San Francisco, received the ASH-Harold Amos Medical Faculty Development Program Award.

A free nurse navigation service helped overcome barriers to clinical trial enrollment for patients with blood cancer, according to study results published in JCO Oncology Practice.

Clinicians who treat blood cancers often disagree whether chimeric antigen receptor T-cell therapies are a potential replacement for hematopoietic stem cell transplant.